角膜宁滴眼液治疗超声乳化白内障摘出术后角膜上皮损伤

目的观察角膜宁滴眼液对超声乳化白内障摘出术后角膜上皮损伤的治疗效果。方法随机将42例超声乳化白内障术后出现角膜上皮损伤患者分为两组,一组常规术后用药,一组加用角膜宁滴眼液,观察两组患者症状的改善和角膜上皮修复情况。结果加用角膜宁滴眼液组症状轻,角膜上皮修复快。结论给超声乳化术后角膜损伤患者加用角膜宁滴眼液,可改善症状,促进角膜上皮愈合。     

塑料滴眼剂瓶生产工艺研究

针对塑料滴眼剂瓶普遍存在的质量问题,重新设计加工了1套θ9．2mm的吹针套,对塑料滴眼剂瓶的瓶口大小进行改进,并优选了塑料滴眼剂瓶滴嘴配方和生产工艺参数。结果表明,塑料滴眼剂瓶滴嘴与瓶口的配合过盈量合理,耐应力开裂参数F50由原来的4h增加到244h,克服了塑料滴眼剂瓶滴嘴因内应力大而出现的开裂现象。     

Comment on “Topical Delivery of Avastin to the Posterior Segment of the Eye In Vivo Using Annexin A5‐Associated Liposomes”: Topical Liposomal Bevacizumab Results in Negligible Retinal Concentrations

The previously published report suggests that liposomes, functionalized with annexin‐5, can deliver bevacizumab to the retina after topical administration as eyedrops. Topical delivery of bevacizumab would be an attractive alternative to the current treatment that involves monthly intravitreal injections to the eye. In this Comment, the retinal concentrations of topically applied liposomal bevacizumab are compared to the levels reached after intravitreal injections. The comparison reveals that the topical liposomal delivery results in retinal bevacizumab concentrations that are about 3–5 orders of magnitude below the lowest bevacizumab concentrations during clinical treatment with intravitreal injections. Major improvement is needed before topical bevacizumab delivery can be considered clinically feasible.